{"id":9915,"date":"2025-05-26T20:29:46","date_gmt":"2025-05-26T20:29:46","guid":{"rendered":"https:\/?page_id=9915"},"modified":"2025-06-06T16:55:08","modified_gmt":"2025-06-06T16:55:08","slug":"inflammatory-diseases-2","status":"publish","type":"page","link":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/","title":{"rendered":"Inflammatory Diseases"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tInflammatory Diseases\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h1>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Chronic inflammatory diseases, including conditions such as inflammatory bowel disease (IBD), psoriasis, ankylosing spondylitis, and systemic vasculitis, affect millions and often overlap with autoimmune and metabolic disorders. Biopharma companies are developing advanced biologics, small molecules, and precision diagnostics to modulate inflammation, block key pathways, and offer lasting symptom relief with fewer side effects.<\/p>

\u00a0<\/p>

Key Focus Areas<\/b>:<\/h5>

\u00a0<\/p>

  • Cytokine Inhibitors<\/strong>
    Targeting central pro-inflammatory cytokines like TNF-\u03b1, IL-6, IL-1\u03b2, IL-17, IL-23, and IL-36 to reduce tissue damage and immune overactivation.<\/p><\/li>

  • JAK & TYK Inhibitors<\/strong>
    Oral small molecules disrupting intracellular signaling in inflammation pathways; used across RA, IBD, and dermatologic diseases.<\/p><\/li>

  • Anti-Integrins & Cell Trafficking Blockers<\/strong>
    Monoclonal antibodies (e.g., vedolizumab, natalizumab) that prevent immune cell migration into inflamed tissues like the gut and CNS.<\/p><\/li>

  • S1P Receptor Modulators<\/strong>
    Small molecules that trap lymphocytes in lymph nodes to reduce systemic inflammation, used in IBD and multiple sclerosis.<\/p><\/li>

  • IL-23 \/ IL-17 Axis Modulation<\/strong>
    Highly effective in treating psoriasis, psoriatic arthritis, and Crohn\u2019s disease by selectively targeting Th17-related inflammation.<\/p><\/li>

  • Microbiome-Inflammation Interventions<\/strong>
    Therapies aimed at restoring gut flora balance to regulate systemic immune activation, especially in IBD and metabolic inflammation.<\/p><\/li>

  • Inflammasome Inhibitors<\/strong>
    Targeting NLRP3 and related inflammasomes to prevent the release of IL-1\u03b2 and IL-18 in autoinflammatory diseases.<\/p><\/li>

  • Complement Pathway Blockade<\/strong>
    Therapies targeting components like C5 or C3 to treat vasculitis, paroxysmal nocturnal hemoglobinuria (PNH), and rare inflammatory syndromes.<\/p><\/li>

  • Neutrophil and Macrophage Modulation<\/strong>
    Therapeutic agents designed to reduce innate immune cell activation and their downstream inflammatory effects.<\/p><\/li>

  • Precision Biomarker Development<\/strong>
    Identifying inflammatory endotypes and biomarkers (e.g., calprotectin, CRP, cytokine signatures) to personalize treatment plans.<\/p><\/li>

  • Others<\/p><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Chronic inflammatory diseases, including conditions such as inflammatory bowel disease (IBD), psoriasis, ankylosing spondylitis, and systemic vasculitis, affect millions and often overlap with autoimmune and metabolic disorders. Biopharma companies are developing advanced biologics, small molecules, and precision diagnostics to modulate inflammation, block key pathways, and offer lasting symptom relief with fewer side effects. Key Focus […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9915","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nInflammatory Diseases - Alliance for Immunology Innovations (AII)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inflammatory Diseases - Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"og:description\" content=\"Chronic inflammatory diseases, including conditions such as inflammatory bowel disease (IBD), psoriasis, ankylosing spondylitis, and systemic vasculitis, affect millions and often overlap with autoimmune and metabolic disorders. Biopharma companies are developing advanced biologics, small molecules, and precision diagnostics to modulate inflammation, block key pathways, and offer lasting symptom relief with fewer side effects. Key Focus […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T16:55:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/inflammatory-diseases-2\\\/\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/inflammatory-diseases-2\\\/\",\"name\":\"Inflammatory Diseases - Alliance for Immunology Innovations (AII)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\"},\"datePublished\":\"2025-05-26T20:29:46+00:00\",\"dateModified\":\"2025-06-06T16:55:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/inflammatory-diseases-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/inflammatory-diseases-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/inflammatory-diseases-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inflammatory Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\",\"name\":\"Alliance for Immunology Innovations (AII)\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inflammatory Diseases - Alliance for Immunology Innovations (AII)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/","og_locale":"en_US","og_type":"article","og_title":"Inflammatory Diseases - Alliance for Immunology Innovations (AII)","og_description":"Chronic inflammatory diseases, including conditions such as inflammatory bowel disease (IBD), psoriasis, ankylosing spondylitis, and systemic vasculitis, affect millions and often overlap with autoimmune and metabolic disorders. Biopharma companies are developing advanced biologics, small molecules, and precision diagnostics to modulate inflammation, block key pathways, and offer lasting symptom relief with fewer side effects. Key Focus […]","og_url":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/","og_site_name":"Alliance for Immunology Innovations (AII)","article_modified_time":"2025-06-06T16:55:08+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/","url":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/","name":"Inflammatory Diseases - Alliance for Immunology Innovations (AII)","isPartOf":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website"},"datePublished":"2025-05-26T20:29:46+00:00","dateModified":"2025-06-06T16:55:08+00:00","breadcrumb":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eutranslationalmedicine.org\/aii\/inflammatory-diseases-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eutranslationalmedicine.org\/aii\/"},{"@type":"ListItem","position":2,"name":"Inflammatory Diseases"}]},{"@type":"WebSite","@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website","url":"https:\/\/eutranslationalmedicine.org\/aii\/","name":"Alliance for Immunology Innovations (AII)","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eutranslationalmedicine.org\/aii\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/comments?post=9915"}],"version-history":[{"count":8,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9915\/revisions"}],"predecessor-version":[{"id":10044,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9915\/revisions\/10044"}],"wp:attachment":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/media?parent=9915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}